SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support […]
Author: Ken Dropiewski
Sequana Medical announces grant of additional DSR® patent in United States
Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. US patent number 11,559,618 B2 has been granted on 24 […]
CIS Launches National Cardiology Platform in Partnership With Lee Equity Partners
HOUMA, La.–(BUSINESS WIRE)–Cardiovascular Institute of the South (CIS), one of the largest independent cardiovascular practices in the country, announced the launch of a national cardiovascular platform, Cardiovascular Logistics, in partnership with private equity firm Lee Equity Partners, headquartered in New York City. The launch of Cardiovascular Logistics will build and […]
Bayer Partners with Huma on Bayer® Aspirin Heart Risk Assessment Online Educational Tool to Raise Awareness of Heart Health and its Risk Factors
Huma’s predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education NEW YORK, Feb. 1, 2023 /PRNewswire/ — Huma Therapeutics Limited (“Huma”), a leading global digital health company, and Bayer, a leading global life sciences company, have partnered to develop the Bayer Aspirin […]
Occlutech Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe
SCHAFFHAUSEN, CH / ACCESSWIRE / January 31, 2023 / Occlutech Holding AG Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market. The first patient has now been enrolled in the global US study OCCLUFLEX in […]
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low. Adjusted for constant currency, Core non-COVID 2022 product sales were within 5% of that achieved in 2021 and greater than 30% increased from pre-pandemic 2019 PRINCETON, N.J., Jan. 31, 2023 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment […]
VentureMed Group Raises Bridge Financing and Embarks on 2023 Objectives
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the company has raised bridge financing to support its 2023 objectives. Endeavour Vision and RiverVest Venture […]
Mindray Unveils Next-generation BeneHeart Defibrillation Solutions to Raise Standards for Resuscitation
SHENZHEN, China, Jan. 31, 2023 /PRNewswire/ — Mindray, a global leading medical device solutions provider, today announces the launch of next-generation BeneHeart series defibrillators, the BeneHeart D60 and D30. The new BeneHeart defibrillators aim to raise the standards for resuscitation with superior reliability, expert comprehensive diagnosis and monitoring tools, and introduce a […]
Integer Holdings Corporation Announces 2022 Preliminary Financial Results
~ Preliminary fourth quarter 2022 sales increase of 18% to 19% versus 2021 ~ ~ Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call ~ PLANO, Texas, Jan. 30, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource manufacturer, announces preliminary financial […]
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2022 NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the second quarter ended December 31, 2022. Financial Highlights Revenue from royalties […]



